in 66 countries, including 5,000 in France.
98% of Servier medicines
active ingredients are synthesized in its own plant in Bolbec-Baclair in France.
100 million patients
treated each day worldwide with Servier medicines.
5 major R&D areas
cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes.
30 drug candidates
in clinical development, including 16 new molecular entities.
A strong international presence
95% of revenue from brand-name medicines.
16 chemical and pharmaceutical production sites
15 International Centers for Therapeutic Research
and 3 research institutes (2 in France and 1 in Hungary).
€4,615 billion euros in revenue
comprising €3.2 billion for brand-name medicines and €1.4 billion for generic medicines.
25 % of revenue from brand-name medicines invested in R&D
each year on average, excluding generics.
No. 1 independent French pharmaceutical company
33rd largest pharmaceutical company worldwide.
A leader position in cardiology in France
no. 2 in Europe, No. 6 in the world .
Participation reached 23,2% of the trade balance surplus in France
In pharmaceuticals and fine chemicals (brand-name medicines), amounting to €1.5 billion.